FDA — authorised 9 December 1991
- Application: BLA103000
- Marketing authorisation holder: ALLERGAN
- Status: supplemented
FDA authorised Botox on 9 December 1991 · 62,880 US adverse-event reports
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Yes. FDA authorised it on 9 December 1991; FDA has authorised it.
ALLERGAN holds the US marketing authorisation.